BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9

Benzinga Newsdesk www.benzinga.com Positive 59.1%

Neg 0% Neu 0% Pos 59.1%

BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.